ReviewFrontiers in immunology2026
Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: The emergence of multidrug-resistant tuberculosis (MDR-TB) and limitations of current antibiotic therapies highlight the urgent need for novel treatment strategies. While immunotherapy has revolutionized cancer treatment, its potential in TB remains underexplored, with existing reviews focusing narrowly on vaccines and phage therapy. A comprehensive synthesis of TB immunotherapy advancements is critical to guide clinical translation. Content: Tuberculosis (TB) has been recognized as one of the earliest diseases treated with immunotherapy. The BCG vaccine played a crucial role in controlling TB epidemics for a long period. However, progress in TB immunotherapy stagnated due to the attenuation of BCG strains and the long-standing neglect in TB immunology research. In recent years, advances in TB and immunology research, including novel immunological theories such as trained immunity, alongside breakthroughs in various immunotherapies for cancer treatment, have provided new perspectives for TB treatment. This review summarizes the immune response to TB, including roles of macrophages, T cells, and nonclassical immune cells. It evaluates progress in cell therapy, antibody therapy, microbial therapy, vaccines, and cytokine therapy. Clinical trials, mechanisms, and challenges (e.g., immune exhaustion, antigen heterogeneity) of TB immunotherapy are analyzed, drawing parallels with cancer immunotherapy. Conclusions: Immunotherapy offers multifaceted strategies to overcome
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.